Resources: GLP-1s | Beta Cells in Diabetes

ResourcesGLP-1s RSS

Resource Library

View the Full Resource List

Search Resources

Expert-Selected
All GLP-1s

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial.

Bunck, Mathijs C; Diamant, Michaela; Cornér, Anja; Eliasson, Bjorn; Malloy, Jaret L; Shaginian, Rimma M; Deng, Wei; Kendall, David M; Taskinen, Marja-Riitta; Smith, Ulf; Yki-Järvinen, Hannele; Heine, Robert J

Diabetes care; 2009 May;32(5):762-8. PMID: 19196887;

Category: Interventions / GLP-1s;

Tags: GLP-1 agonists, glycemic control, metformin
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

Garber, Alan; Henry, Robert; Ratner, Robert; Garcia-Hernandez, Pedro A; Rodriguez-Pattzi, Hiromi; Olvera-Alvarez, Israel; Hale, Paula M; Zdravkovic, Milan; Bode, Bruce; ,

Lancet; 2009 Feb 7;373(9662):473-81. PMID: 18819705;

Category: Interventions / GLP-1s;

Tags: GLP-1 agonists, glycemic control, sulfonylureas (SUs)
Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes.

Fehse, Frauke; Trautmann, Michael; Holst, Jens J; Halseth, Amy E; Nanayakkara, Nuwan; Nielsen, Loretta L; Fineman, Mark S; Kim, Dennis D; Nauck, Michael A

The Journal of clinical endocrinology and metabolism; 2005 Nov;90(11):5991-7. PMID: 16144950;

Category: Interventions / GLP-1s;

Tags: beta cell pathophysiology, GLP-1 agonists, glycemic control
Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.

Heine, Robert J; Van Gaal, Luc F; Johns, Don; Mihm, Michael J; Widel, Mario H; Brodows, Robert G; ,

Annals of internal medicine; 2005 Oct 18;143(8):559-69. PMID: 16230722;

Category: Interventions / GLP-1s;

Tags: GLP-1 agonists, glycemic control, insulin therapy
Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women.

Buchanan, Thomas A; Xiang, Anny H; Peters, Ruth K; Kjos, Siri L; Marroquin, Aura; Goico, Jose; Ochoa, Cesar; Tan, Sylvia; Berkowitz, Kathleen; Hodis, Howard N; Azen, Stanley P

Diabetes; 2002 Sep;51(9):2796-803. PMID: 12196473;

Category: Interventions / GLP-1s;

Tags: beta cell pathophysiology, GLP-1 agonists, glycemic control, prediabetes

Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.

Buse, John B; Bergenstal, Richard M; Glass, Leonard C; Heilmann, Cory R; Lewis, Michelle S; Kwan, Anita Y M; Hoogwerf, Byron J; Rosenstock, Julio

Annals of internal medicine; 2011 Jan 18;154(2):103-12. PMID: 21138825;

Category: Interventions / GLP-1s;

Tags: GLP-1 agonists, glycemic control, insulin therapy
Calcineurin signaling regulates human islet {beta}-cell survival.

Soleimanpour, Scott A; Crutchlow, Michael F; Ferrari, Alana M; Raum, Jeffrey C; Groff, David N; Rankin, Matthew M; Liu, Chengyang; De León, Diva D; Naji, Ali; Kushner, Jake A; Stoffers, Doris A

The Journal of biological chemistry; 2010 Dec 17;285(51):40050-9. PMID: 20943662;

Category: Interventions / GLP-1s;

Tags: beta cell pathophysiology, GLP-1 agonists
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.

Bergenstal, Richard M; Wysham, Carol; Macconell, Leigh; Malloy, Jaret; Walsh, Brandon; Yan, Ping; Wilhelm, Ken; Malone, Jim; Porter, Lisa E

Lancet; 2010 Aug 7;376(9739):431-9. PMID: 20580422;

Category: Interventions / GLP-1s;
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.

Diamant, Michaela; Van Gaal, Luc; Stranks, Stephen; Northrup, Justin; Cao, Dachuang; Taylor, Kristin; Trautmann, Michael

Lancet; 2010 Jun 26;375(9733):2234-43. PMID: 20609969;

Category: Interventions / GLP-1s;
DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.

Buse, John B; Drucker, Daniel J; Taylor, Kristin L; Kim, Terri; Walsh, Brandon; Hu, Hao; Wilhelm, Ken; Trautmann, Michael; Shen, Larry Z; Porter, Lisa E

Diabetes care; 2010 Jun;33(6):1255-61. PMID: 20215461;

Category: Interventions / GLP-1s;
Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.

Drab, Scott R

Pharmacotherapy; 2010 Jun;30(6):609-24. PMID: 20500049;

Category: Interventions / GLP-1s;
Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy.

Parks, Mary; Rosebraugh, Curtis

The New England journal of medicine; 2010 Mar 4;362(9):774-7. PMID: 20164475;

Category: Interventions / GLP-1s;
Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study.

DeFronzo, R A; Banerji, M A; Bray, G A; Buchanan, T A; Clement, S; Henry, R R; Kitabchi, A E; Mudaliar, S; Musi, N; Ratner, R; Reaven, P; Schwenke, D C; Stentz, F D; Tripathy, D

Diabetologia; 2010 Mar;53(3):435-45. PMID: 20012012;

Category: Interventions / GLP-1s;
Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits.

Drucker, Daniel J; Sherman, Steven I; Gorelick, Fred S; Bergenstal, Richard M; Sherwin, Robert S; Buse, John B

Diabetes care; 2010 Feb;33(2):428-33. PMID: 20103558;

Category: Interventions / GLP-1s;
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.

Russell-Jones, D; Vaag, A; Schmitz, O; Sethi, B K; Lalic, N; Antic, S; Zdravkovic, M; Ravn, G M; Simó, R

Diabetologia; 2009 Oct;52(10):2046-55. PMID: 19688338;

Category: Interventions / GLP-1s;

Tags: GLP-1 agonists, insulin therapy

Betacell

A resource for physicians established by the Endocrine Society

Text Size:

ResourcesGLP-1s RSS

Resource Library

Search Resources

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial.

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes.

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women.

Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.

Calcineurin signaling regulates human islet {beta}-cell survival.

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.

Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.

Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy.

Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study.

Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits.

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.